Safety and efficacy of iStent Inject trabecular micro-bypass stents in combination with phacoemulsification for chronic open angle glaucoma associated with cataract

被引:0
|
作者
Cela, D. [1 ,2 ]
Brasnu, E. [1 ,2 ]
Hamard, P. [1 ,2 ]
Baudouin, C. [1 ,2 ,3 ]
Labbe, A. [1 ,2 ,3 ]
机构
[1] Quinze Vingts Natl Ophthalmol Hosp, Dept Ophthalmol 3, INSERM, IHU Foresight,DGOS C 1423, 28 Rue Charenton, F-75012 Paris, France
[2] Sorbonne Univ, CNRS, INSERM, Inst Vis,IHU Foresight, Paris, France
[3] Univ Versailles St Quentin Yvelines, Ambroise Pare Hosp, AP HP, Dept Ophthalmol,IHU Foresight, Boulogne Billancourt, France
来源
JOURNAL FRANCAIS D OPHTALMOLOGIE | 2023年 / 46卷 / 02期
关键词
Minimally invasive; glaucoma surgery; Open-angle; Trabecular stent; Phacoemulsification; ONE-YEAR OUTCOMES; INTRAOCULAR-PRESSURE; IMPLANTATION; SURGERY; EXTRACTION;
D O I
10.1016/j.jfo.2022.08.007
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background. - The goal of this study was to assess the efficacy and safety of phacoemulsification combined with iStent Inject((R)) implantation for the treatment of chronic open-angle glaucoma controlled on topical anti-glaucoma medications and associated with cataract. Methods. - This study was a retrospective analysis of patients who underwent phacoemulsification and implantation of an iStent Inject((R)) for chronic open-angle glaucoma associated with cataract. For all patients, pre- and postoperative characteristics, including number of glaucoma medications and intraocular pressure (IOP), were compared using Paired-sample t-tests and Wilcoxon signed-rank tests, respectively. Postoperative visits were scheduled at 7 days and 1, 3, 6, and 12 months after surgery. Results. - Forty-nine eyes of 39 patients were included in the study. Mean preoperative IOP at baseline was 16.3 +/- 4.3 mmHg (range, 10-29 mmHg) with a mean of 2.2 +/- 1.0 mmHg antiglaucoma medications. At 1 month, the mean IOP reduction was 16% (P < 0.05) along with an 18.7% reduction in the mean number of medications. At 6 months, the mean IOP was 12.8 +/- 2.6, witha mean of 1.1 +/- 0.9 antiglaucoma medications. The mean IOP reduction at 6 months was 22% (P < 0.05) along with a 49% reduction in the mean number of medications. At 12 months, themean IOP was 13.8 +/- 2.5 with a mean of 1.1 +/- 1.2 medications. The mean IOP reduction at 12 months was 15% (P < 0.05) along with a 47% reduction in the mean number of medications. No severe device-related side effects were observed. Conclusions. - iStent Inject((R)) implantation combined with phacoemulsification resulted ineffective IOP reduction and medication burden in patients with mild to advanced chronic open-angle glaucoma and preoperative IOP well controlled with topical hypotensive medications. (c) 2023 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:129 / 136
页数:8
相关论文
共 50 条
  • [41] Long-term outcomes of two first-generation trabecular micro-bypass stents (iStent) with phacoemulsification in primary open-angle glaucoma: eight-year results
    Ali Salimi
    Harrison Watt
    Paul Harasymowycz
    Eye and Vision, 8
  • [42] Long-term outcomes of two first-generation trabecular micro-bypass stents (iStent) with phacoemulsification in primary open-angle glaucoma: eight-year results
    Salimi, Ali
    Watt, Harrison
    Harasymowycz, Paul
    EYE AND VISION, 2021, 8 (01)
  • [43] Cost-effectiveness analysis of iStent trabecular micro-bypass stent for patients with open-angle glaucoma in Colombia
    Ordonez, Jaime E.
    Ordonez, Angelica
    Osorio, Urpy M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (02) : 329 - 340
  • [44] Five-Year Outcomes Prospective Study of Two First-Generation Trabecular Micro-Bypass Stents (iStent®) in Open-Angle Glaucoma
    Saheb, Hady
    Donnenfeld, Eric D.
    Solomon, Kerry D.
    Voskanyan, Lilit
    Chang, David F.
    Samuelson, Thomas W.
    Ahmed, Iqbal Ike K.
    Katz, L. Jay
    CURRENT EYE RESEARCH, 2021, 46 (02) : 224 - 231
  • [45] Mid-Term Evaluation of iStent Inject® Trabecular Micro-Bypass Stent Implantation with or without Phacoemulsification: A Retrospective Study
    Silveira Seixas, Regina Cele
    Balbino, Marcos
    Neto, Alberto Basile
    Almeida Costa, Amanda de Alcantara
    da Silva Jordao, Marcelo Lopes
    Abil Russ, Heloisa Helena
    CLINICAL OPHTHALMOLOGY, 2020, 14 : 4403 - 4413
  • [46] Two Year Efficacy of Trabecular Micro-Bypass Stent in Patients with Glaucoma and Cataract
    Sayegh, Yoseph
    Baciu, Paul D.
    Vanner, Elizabeth A.
    Maharaj, Arindel S.
    Wellik, Sarah R.
    Kishor, Krishna
    Junk, Anna K.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [47] Co-existent open-angle glaucoma and cataract: Treatment by cataract surgery and the iStent Trabecular Bypass Micro Stent
    Spiegel, D
    Wetzel, W
    Sturmer, J
    Hoh, H
    Neuhann, T
    Garcia-Sanchez, J
    Hill, RA
    Niksch, B
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
  • [48] Comparative evaluation of iStent versus iStent inject W combined with phacoemulsification in open angle glaucoma
    Morita, Shuu
    Sakanishi, Yoshihito
    Riyu, Ikari
    Watanabe, Satoshi
    Ebihara, Nobuyuki
    PLOS ONE, 2024, 19 (02):
  • [49] Unplanned Intracanalicular Implantation of a Second-Generation Trabecular Micro-Bypass (iStent inject)
    Gravina, Daniela Marcelo
    Paletta Guedes, Ricardo Augusto
    Paletta Guedes, Vanessa Maria
    OPHTHALMOLOGY GLAUCOMA, 2021, 4 (02): : 125 - 125
  • [50] Coexistent primary open-angle glaucoma and cataract: interim analysis of a trabecular micro-bypass stent and concurrent cataract surgery
    Spiegel, Detlev
    Wetzel, Wolfgang
    Neuhann, Thomas
    Stuermer, Jorg
    Hoeh, Helmut
    Garcia-Feijoo, Julian
    Martinez-De-La-Casa, Jose Maria
    Garcia-Sanchez, Julian
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2009, 19 (03) : 393 - 399